Black Hawk Acquisition (BKHA) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Black Hawk Acquisition is the larger company by market cap ($54.0 million vs $52.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | BKHA | IMA |
|---|---|---|
| Share price | $13.00 | $4.61 |
| Market cap | $54.00M | $52.43M |
| 1-day change | +5.69% | -1.91% |
| YTD return | — | -33.19% |
| 1-year return | — | -44.72% |
| 5-year return | — | -96.83% |
| P/E ratio (TTM) | 39.39 | — |
| EPS (TTM) | $0.33 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $9.10 |
| 52-week low | $11.00 | $3.94 |
| Distance from 52-week high | -1.14% | -49.34% |
| Average volume | 3.63K | 12.81K |
| Shares outstanding | 4.15M | 11.37M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
BKHA vs IMA FAQ
Which is bigger, Black Hawk Acquisition or ImageneBio?
Black Hawk Acquisition (BKHA) is larger, with a market capitalization of $54.00M compared with $52.43M for ImageneBio (IMA).
Are Black Hawk Acquisition and ImageneBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.